首页> 外文期刊>Analytical chemistry >Characterization and Stability Study of Polysorbate 20 in Therapeutic Monoclonal Antibody Formulation by Multidimensional Ultrahigh- Performance Liquid Chromatography-Charged Aerosol Detection- Mass Spectrometry
【24h】

Characterization and Stability Study of Polysorbate 20 in Therapeutic Monoclonal Antibody Formulation by Multidimensional Ultrahigh- Performance Liquid Chromatography-Charged Aerosol Detection- Mass Spectrometry

机译:多维超高效液相色谱-带电气溶胶检测-质谱法在治疗性单克隆抗体制剂中聚山梨酯20的表征和稳定性研究

获取原文
获取原文并翻译 | 示例
       

摘要

Polysorbate 20 is a nonionic surfactant commonly used in the formulation of therapeutic monoclonal antibodies (mAb) to prevent protein denaturation and aggregation. It is critical to understand the molecular heterogeneity and stability of polysorbate 20 in mAb formulations as polysorbate can gradually degrade in aqueous solution over time by multiple pathways losing surfactant functions and leading to protein aggregation. The molecular heterogeneity of polysorbate and the interference from proteins and the excipient in the formulation matrix make it a challenge to study polysorbate in protein formulations. In this work, the characterization and stability study of polysorbate 20 in the presence of mAb formulation sample matrix is first reported using two-dimensional liquid chromatography (2DLC) coupled with charged aerosol detection (CAD) and mass spectrometry (MS) detection. A mixed-mode column that has both anion-exchange and reversed-phase properties was used in the first dimension to separate protein and polysorbate in the formulation sample, while polysorbate 20 esters were trapped online and then analyzed using an reversed-phase ultrahigh-performance liquid chromatography (RP-UHPLC) column in the second dimension to further separate the ester species. The MS served as the third dimension to further resolve as well as to identify the polysorbate ester subspecies. Another 2DLC method using a cation-exchange column in the first dimension and the same RP-UHPLC method in the second dimension was developed to analyze the degradation products of polysorbate 20. Stability samples of a protein drug product were studied using these two 2DLC-CAD-MS methods to separate, identify, and quantify the multiple ester species in polysorbate 20 and also to monitor the change of their corresponding degradants. We found different polysorbate esters degrade at different rates, and importantly, the degradation rates for some esters are different in the protein formulation compared to a placebo that has no protein. The multidimensional UHPLC-CAD-MS approach provides insights into the heterogeneous stability behaviors of polysorbate 20 subspecies in real-time stability samples of a mAb formulation.
机译:聚山梨酯20是非离子表面活性剂,通常用于治疗性单克隆抗体(mAb)的制剂中,以防止蛋白质变性和聚集。了解mAb配方中的聚山梨酯20的分子异质性和稳定性至关重要,因为聚山梨酯可通过多种途径丧失表面活性剂功能并导致蛋白质聚集,随着时间的推移在水溶液中逐渐降解。聚山梨酸酯的分子异质性以及蛋白质和赋形剂在制剂基质中的干扰,使得研究蛋白质制剂中的聚山梨酸酯成为一项挑战。在这项工作中,首先使用二维液相色谱(2DLC)结合带电气溶胶检测(CAD)和质谱(MS)检测报告了在mAb制剂样品基质存在下的聚山梨酯20的表征和稳定性研究。一维使用具有阴离子交换和反相特性的混合模式色谱柱来分离制剂样品中的蛋白质和聚山梨酯,同时在线捕获聚山梨酯20酯,然后使用反相超高性能色谱柱进行分析。二维液相色谱(RP-UHPLC)柱进一步分离酯类。 MS作为第三维,进一步解析以及确定了聚山梨酸酯亚种。开发了另一种使用第一维阳离子交换柱和第二维使用RP-UHPLC方法的2DLC方法,以分析聚山梨酯20的降解产物。使用这两种2DLC-CAD研究了蛋白质药物产品的稳定性样品-MS方法可以分离,鉴定和定量聚山梨酯20中的多种酯类,还可以监测其相应降解物的变化。我们发现不同的聚山梨酸酯的降解速率不同,重要的是,与不含蛋白质的安慰剂相比,蛋白质配方中某些酯的降解速率有所不同。多维UHPLC-CAD-MS方法可洞察mAb制剂实时稳定性样品中聚山梨酯20个亚种的异质稳定性行为。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号